DDInter1166 DDInter927
Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a number of unique characteristics that have led to its increased use in the last two decades; in particular, methadone has a lower risk of neuropsychiatric toxicity compared to other opioids (due to a lack of active metabolites), minimal accumulation in renal failure, good bioavailability, low cost, and a long duration of action.[F4685,F4688,F4691,A185885,A185900,A185903] Due to its unique mechanism of action, methadone is particularly useful for the management of hard to treat pain syndromes
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Methadone {u} (Compound) resembles {v} (Compound) Diphenoxylate
Methadone {u} (Compound) resembles {v} (Compound) Ethopropazine
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Methadone {u} (Compound) binds {v} (Gene) CYP2B6
Methadone {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Methadone {u} (Compound) causes {v} (Side Effect) Cardiomyopathy
Methadone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Methadone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Peginterferon alfa-2a
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Methadone {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Methadone (Compound) resembles Diphenoxylate (Compound)
Methadone (Compound) resembles Ethopropazine (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Trospium
Methadone (Compound) binds CYP2B6 (Gene)
Methadone (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Methadone (Compound) causes Cardiomyopathy (Side Effect)
Methadone may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride
Methadone may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2a
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Methadone may lead to a major life threatening interaction when taken with Naltrexone